Log in

NYSE:IMVIMV Stock Price, Forecast & News

$3.53
-0.10 (-2.75 %)
(As of 05/25/2020 04:00 PM ET)
Add
Compare
Today's Range
$3.36
Now: $3.53▼
$3.70
50-Day Range
$1.52
MA: $2.23▼
$3.53
52-Week Range
$1.35
Now: $3.53▼
$5.12
Volume522,065 shs
Average Volume224,939 shs
Market Capitalization$211.20 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
IMV, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 4.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.41 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSE
Industry Biotechnology
Sub-IndustryN/A
SectorHealth Technology
Current SymbolNYSE:IMV
Previous Symbol
CUSIPN/A
CIKN/A
WebN/A
Phone(902) 492-1819

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

EmployeesN/A
Outstanding Shares59,830,000
Market Cap$211.20 million
Next Earnings Date8/13/2020 (Estimated)
OptionableNot Optionable
IMV Rates by TradingView

Receive IMV News and Ratings via Email

Sign-up to receive the latest news and ratings for IMV and its competitors with MarketBeat's FREE daily newsletter.

IMV (NYSE:IMV) Frequently Asked Questions

How has IMV's stock been impacted by COVID-19 (Coronavirus)?

IMV's stock was trading at $2.38 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, IMV stock has increased by 48.3% and is now trading at $3.53. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IMV?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IMV.

When is IMV's next earnings date?

IMV is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for IMV.

How were IMV's earnings last quarter?

Imv Inc (NYSE:IMV) announced its earnings results on Monday, March, 30th. The company reported ($0.13) EPS for the quarter, missing the Zacks' consensus estimate of ($0.10) by $0.03. The company had revenue of $0.10 million for the quarter, compared to analysts' expectations of $0.03 million. View IMV's earnings history.

What price target have analysts set for IMV?

7 analysts have issued twelve-month price objectives for IMV's stock. Their forecasts range from $3.00 to $13.00. On average, they expect IMV's stock price to reach $7.42 in the next twelve months. This suggests a possible upside of 110.1% from the stock's current price. View analysts' price targets for IMV.

What are Wall Street analysts saying about IMV stock?

Here are some recent quotes from research analysts about IMV stock:
  • 1. According to Zacks Investment Research, "IMV Inc. is a clinical-stage immuno-oncology company. Its proprietary drug development platform provides a patented delivery formulation which enables controlled and prolonged exposure of antigens to the immune system. The company's pipeline consists of DPX-Survivac, DPX-E7 and DPX-RSV which are in clinical stage. IMV Inc. is based in Halifax, Canada. " (3/25/2020)
  • 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $11.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities in the U.S. for only DPX-Survivac, the leading asset, in ovarian cancer (approximately 43% valuation contribution, 30% chance of success), DLBCL (15% valuation contribution, 15% chance of success), and the indications in the basket trial (41% valuation contribution, 10% chance of success)." (6/12/2019)

Has IMV been receiving favorable news coverage?

Media coverage about IMV stock has been trending somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. IMV earned a news impact score of 1.4 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the stock's share price in the near term. View the latest news aboutIMV.

Who are some of IMV's key competitors?

What other stocks do shareholders of IMV own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IMV investors own include Inovio Pharmaceuticals (INO), Matinas BioPharma (MTNB), Gilead Sciences (GILD), Nokia Oyj (NOK), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Cidara Therapeutics (CDTX), Vaxart (VXRT), ADMA Biologics (ADMA) and Amplify Energy (AMPY).

Who are IMV's key executives?

IMV's management team includes the following people:
  • Frederic Ors, CEO, Director & Chief Business Officer
  • Pierre Labbé, Chief Financial Officer
  • Gabriela Nicola Rosu, Chief Medical Officer
  • Marianne Stanford, Vice President-Research
  • Joseph Sullivan, Senior Vice President-Business Development

What is IMV's stock symbol?

IMV trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMV."

Who are IMV's major shareholders?

IMV's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (0.43%), First Manhattan Co. (0.17%), Wells Fargo & Company MN (0.04%), JPMorgan Chase & Co. (0.05%), Raymond James & Associates (0.05%) and 1832 Asset Management L.P. (0.03%).

Which institutional investors are selling IMV stock?

IMV stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co..

Which institutional investors are buying IMV stock?

IMV stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Wells Fargo & Company MN, JPMorgan Chase & Co., Raymond James & Associates, and 1832 Asset Management L.P..

How do I buy shares of IMV?

Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IMV's stock price today?

One share of IMV stock can currently be purchased for approximately $3.53.

How big of a company is IMV?

IMV has a market capitalization of $211.20 million.

How can I contact IMV?

The company can be reached via phone at (902) 492-1819.

This page was last updated on 5/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.